Research Article
Toxicity of a Novel Herbomineral Preparation Las01 on Human Cancer Cell Lines and Its Safety Profile in Humans and Animals
Table 2
Effect of chronic administration of Las01 in rats.
| Parameters
| Control
| Las01 | | Group 1 | Group 2 | Group 3 |
| Total WBCcount × 103 mm3
| 7634 ± 520
| 7293 ± 488
| 7335 ± 230
| 7653 ± 422
| Haemoglobin (gm%)
| 13.13 ± 1.0
| 12.10 ± 2.85
| 12.65 ± 1.0
| 13.16 ± 1.23
| Bilirubin total (mg/dL)
| 0.29 ± 0.12
| 0.28 ± 0.14
| 0.30 ± 0.02
| 0.31 ± 0.12
| Bilirubin direct (mg/dL)
| 0.25 ± 0.15
| 0.21 ± 0.12
| 0.28 ± 0.15
| 0.33 ± 0.14
| SGPT (U/L)
| 45.11 ± 11.12
| 46.8 ± 10.5
| 45.66 ± 11.35
| 44.6 ± 12.1
| | SGOT (U/L) | 74.2 ± 12.25 | 73.1 ± 12.6 | 74.2 ± 19.33 | 75.4 ± 14.16 | | ALP (U/L) | 210.2 ± 22.5 | 218.3 ± 44.1 | 219.8 ± 42.5 | 228.2 ± 39.5 | | Albumin (mg/dL) | 3.27 ± 0.32 | 3.31 ± 0.41 | 3.26 ± 0.12 | 3.25 ± 0.41 | | Globulin (mg/dL) | 4.15 ± 0.19 | 4.11 ± 0.10 | 4.10 ± 0.28 | 4.64 ± 0.11 | | Total protein (gm%) | 7.32 ± 0.42 | 7.42 ± 0.28 | 7.36 ± 0.42 | 7.89 ± 0.22 | | BUN (mg/dL) | 65.12 ± 6.29 | 67.22 ± 6.87 | 64.26 ± 7.09 | 65.15 ± 5.8 | | Creatinine (mg/dL) | 0.41 ± 0.02 | 0.42 ± 0.03 | 0.46 ± 0.01 | 0.41 ± 0.06 | Sodium (mEq/L)
| 145.1 ± 2.1 | 144.4 ± 2.39 | 143.6 ± 3.5 | 145.8 ± 2.45 | Potassium (mEq/L)
| 4.8 ± 0. 33 | 4.9 ± 0.34 | 4.2 ± 0. 76 | 4.9 ± 0.01 | | Chloride (mEq/L) | 104.1 ± 1.10 | 108 ± 1.08 | 103.5 ± 4.20 | 104.6 ± 1.34 |
|
|
